Results 181 to 190 of about 36,124 (280)

Clinical Pharmacology and Translational Science Considerations in the Development of Dual‐Payload Antibody Drug Conjugates

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Antibody‐drug conjugates (ADCs) have evolved in the last decade or two from carrying a single chemotherapy payload to carrying highly potent tubulin inhibitors and DNA damaging agents. While the latter have shown success in the clinic, efficacy has been constrained by therapeutic resistance, limited tumor penetration, and suboptimal immune ...
Paulien Ravenstijn, Toru Kakinuma, Salaheldin Hamed, Takeshi Kadokura, Yohei Okada, Srinivasu Poondru   +5 more
wiley   +1 more source

How Survivors of Colorectal Cancer Experience ctDNA Testing and Fear of Recurrence. [PDF]

Psychooncology
McLachlan SA, Hall I, Collins A, Philip J, Gibbs P, Tie J.   +5 more
europepmc   +1 more source

Presurgical levels of circulating tumour DNA in patients with resectable chemotherapy-naïve colorectal liver metastases: association with multiorgan recurrence and survival in the MIRACLE cohort. [PDF]

Br J Surg
Wullaert L, van Leeuwen L, de Weerd V, Van M, Oomen-de Hoop E, Kraan J, Jansen MPHM, Martens JWM, Grünhagen DJ, Verheul HMW, Verhoef C, Wilting SM.   +11 more
europepmc   +1 more source

Early cancer detection in a large American Cancer Society cohort study: Retrospective analysis of methylated DNA biomarkers

Cancer, Volume 132, Issue 8, 15 April 2026.
ABSTRACT Background Cancer biobank studies can inform the natural history of cancer and possibilities for earlier detection. The authors investigated the detectability of a cell‐free DNA methylation‐based cancer signal in biobanked plasma samples from the large American Cancer Society Cancer Prevention Study 3.
Alpa V. Patel, Gregory Alexander, William L. Dahut, Emily L. Deubler, Eric T. Fung, Earl Hubbell, Rong Jiang, Cari Lichtman, Charles Swanton, Lauren R. Teras, Oliver Venn, Nan Zhang, Christina A. Clarke   +12 more
wiley   +1 more source

Integrating baseline ctDNA-derived tumor metrics enhances risk stratification in HR-positive/HER2-negative advanced breast cancer: a real-world multicenter cohort study from Austria. [PDF]

ESMO Open
Dobrić N, Hasenleithner SO, Suppan C, Klocker EV, Hlauschek D, Graf R, Beichler C, Albertini C, Egle D, Liu D, Starzer AM, Bartsch R, Moser T, Rinnerthaler G, Jost PJ, Heitzer E, Dandachi N, Balic M.   +17 more
europepmc   +1 more source

Detecting TP53 mutations in paired liquid and tissue biopsies from patients with high‐grade serous ovarian carcinoma

International Journal of Cancer, Volume 158, Issue 8, Page 2043-2050, 15 April 2026.
What's New? High‐grade serous ovarian carcinoma is often diagnosed at advanced stages due to non‐specific symptoms and the lack of reliable screening methods. This proof‐of‐concept study introduces a novel TP53 mutation panel using unique molecular identifier‐based next‐generation sequencing for sensitive detection of high‐grade serous ovarian ...
Amanda Olsson Widjaja, Peter Micallef, Maria Lycke, Tobias Österlund, Manuel Luna Santamaría, Julia Hedlund Lindberg, Therese Carlsson, Ulf Gyllensten, Anders Ståhlberg, Benjamin Ulfenborg, Anna Linder, Karin Sundfeldt   +11 more
wiley   +1 more source

The potential survival gain and cost-effectiveness of circulating tumor DNA-guided treatment switching in advanced non-small cell lung cancer: A simulation modeling study. [PDF]

J Liq Biopsy
Jansen JP, Douglas MP, Phillips KA.
europepmc   +1 more source

Liquid Biopsy in Gastrointestinal Cancers: Circulating Tumor DNA for Molecular Residual Disease Assessment and Early Treatment Monitoring. [PDF]

Cancers (Basel)
Safiejko K, Juchimiuk M, Pierko J, Maslyk M, Mucha M, Koda M, Konczuga-Koda L, Radej S, Akcakaya A, Szarpak L.   +9 more
europepmc   +1 more source

Integrating Artificial Intelligence, Circulating Tumor DNA, and Real-World Evidence to Optimize Hematologic Clinical Trials: Toward Adaptive and Learning Trial Designs. [PDF]

Cancers (Basel)
Mahmoud AM, Touti JP, Zaidi SR, Kodipad AA, Deambrogi C.   +4 more
europepmc   +1 more source

Harmonising ctDNA Measurement in Haematological Malignancies: Traceability, Commutability and Reporting. [PDF]

Diagnostics (Basel)
Shibeeb S.
europepmc   +1 more source